Previous cost-effectiveness studies have shown that tPA is good value for money for patients with known stroke onset time.[19,22,38,39] Tung et al. reported an ICER of $23,000/QALY (in 2013 dollars) for tPA treatment in patients with known stroke age between 180–270 minutes. This evidence concerns the gene PLAT and Stroke.